Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Victoria Werth"'
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2e399f643e514ff4b2e5c7efc35b5335
Autor:
Victoria P, Werth, Richard A, Furie, Juanita, Romero-Diaz, Sandra, Navarra, Kenneth, Kalunian, Ronald F, van Vollenhoven, Filippa, Nyberg, Benjamin H, Kaffenberger, Saira Z, Sheikh, Goran, Radunovic, Xiaobi, Huang, George, Clark, Hua, Carroll, Himanshu, Naik, Francois, Gaudreault, Adam, Meyers, Catherine, Barbey, Cristina, Musselli, Nathalie, Franchimont, Victoria, Werth
Publikováno v:
New England journal of medicine, 387(4), 321-3313. Massachussetts Medical Society
New England Journal of Medicine, 387(4), 321-3313. Massachussetts Medical Society
the LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus ', New England Journal of Medicine, vol. 387, no. 4, pp. 321-3313 . https://doi.org/10.1056/NEJMoa2118024
New England Journal of Medicine, 387(4), 321-3313. Massachussetts Medical Society
the LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus ', New England Journal of Medicine, vol. 387, no. 4, pp. 321-3313 . https://doi.org/10.1056/NEJMoa2118024
Blood dendritic cell antigen 2 (BDCA2) is a receptor that is exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of lupus erythematosus. Whether treatment with litifilimab, a humanized monoclonal antibody a
Autor:
Victoria Werth, Mariko Ogawa-Momohara, Ming-Lin Liu, Thomas Vazquez, Meena Sharma, Rachita Pandya, Julianne Kleitsch, Avital Baniel, Rohan Dhiman, Muhammad M. Bashir, DeAnna Diaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::873ab2414f5fde31e196cc89447a0c71
https://doi.org/10.26226/m.641999d55cbd02001a87d9a8
https://doi.org/10.26226/m.641999d55cbd02001a87d9a8
Publikováno v:
Clinical and Experimental Rheumatology.
Dermatomyositis (DM) is an autoimmune disorder in which clinically amyopathic DM, characterised by hallmark cutaneous findings in the absence of clinical weakness, represents 20% of patients. This review will highlight current concepts and recent adv
Autor:
Richard A, Furie, Ronald F, van Vollenhoven, Kenneth, Kalunian, Sandra, Navarra, Juanita, Romero-Diaz, Victoria P, Werth, Xiaobi, Huang, George, Clark, Hua, Carroll, Adam, Meyers, Cristina, Musselli, Catherine, Barbey, Nathalie, Franchimont, Victoria, Werth
Publikováno v:
LILAC Trial Investigators 2022, ' Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus ', The New England journal of medicine, vol. 387, no. 10, pp. 894-904 . https://doi.org/10.1056/NEJMoa2118025
The New England journal of medicine, 387(10), 894-904. Massachussetts Medical Society
The New England journal of medicine, 387(10), 894-904. Massachussetts Medical Society
Antibody-binding of blood dendritic cell antigen 2 (BDCA2), which is expressed exclusively on plasmacytoid dendritic cells, suppresses the production of type I interferon that is involved in the pathogenesis of systemic lupus erythematosus (SLE). The
Autor:
Victoria Werth, Marilyn Pike, Joan Merrill, Eric Morand, Ronald Van Vollenhoven, Coburn Hobar, Nikolay Delev, Vaishali Shah, Brian Sharkey, Thomas Wegman, Ian Catlett, Subhashis Banerjee, Shalabh Singhal
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s114
Introduction: Tyrosine kinase 2 (TYK2) mediates signaling of Type I interferons and IL-23, key cytokines involved in systemic lupus erythematosus (SLE) pathogenesis. Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in multi
Autor:
Christina Bax, DeAnna Diaz, Yubin Li, Thomas Vazquez, Jay Patel, Madison Grinnell, Adarsh Ravishankar, Spandana Maddukuri, Emily Keyes, Daisy Yan, Muhammad Bashir, Victoria Werth
Publikováno v:
SSRN Electronic Journal.
Autor:
Michelle K. Y. Chen, Ravi Vissapragada, Norma Bulamu, Monisha Gupta, Victoria Werth, Deshan Frank Sebaratnam
Publikováno v:
JAMA Dermatology. 158:1013
ImportanceThere is an increasing body of literature that supports the use of rituximab as a first-line steroid-sparing agent in pemphigus vulgaris. However, the cost of rituximab is substantial compared with conventional agents, and there are limited
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB53